Who is sponsoring NCT06799000?

NCT06799000 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT06799000?

Interventions in NCT06799000: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2.

What condition does NCT06799000 study?

NCT06799000 studies Hidradenitis Suppurativa.

Is NCT06799000 still recruiting?

NCT06799000 is currently recruiting now. Last updated 12 March 2026.

Last reviewed 2026-03-12 · How we verify

NCT06799000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Recruiting now Phase 3 Last updated 12 March 2026

What this trial tests

Phase 3 trial testing Remibrutinib Dose A in Hidradenitis Suppurativa in 555 participants. Currently enrolling.

Timeline

31 January 2025

Primary endpoint
31 August 2027

18 January 2028

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	555
Start date	31 January 2025
Primary completion	31 August 2027
Estimated completion	18 January 2028
Sites	145 locations across Italy, Colombia, Malaysia, Taiwan, Poland, Denmark, Mexico, Bulgaria

Drugs / interventions tested

Remibrutinib Dose A — full drug profile →
Remibrutinib Dose B — full drug profile →
Placebo 1 — full drug profile →
Placebo 2 — full drug profile →

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 12 to 100, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current Treatments and Future Directions for Hidradenitis Suppurativa: a Narrative Review of Completed and Ongoing Phase 3 Clinical Trials of Biologic Therapies.
Garg A, Hsiao J, Porter ML, Shi V. · · 2025 · cited 3× · PMID 40681937 · DOI 10.1007/s13555-025-01487-y
Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.
Bechara FG, Marzano AV, Martorell A, van der Zee HH, et al · · 2025 · PMID 40583084 · DOI 10.1007/s13555-025-01462-7

Verify or expand the search:

Other trials of Remibrutinib Dose A

Trials testing the same drug.

NCT06840392 — A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderat · Phase 3 · recruiting

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06799000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 12 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06799000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing